A pain medicine provider has made a bet on a stock with a lot of pain medicine potential and a market capitalization of more than $20 billion.
That stock, called BioMedix, is one of a few stocks that is expected to perform well.
BioMediq, a drugmaker in India, is also one of the largest pharmaceuticals makers in the world.
BioQx, a British drugmaker, is the biggest drugmaker of pain drugs in the U.K. The stock is up 5 percent since the start of the year.
BioXcel, an Israeli maker of pain pills, is up 12 percent.
Both companies have significant revenue potential and are among the biggest pain companies in the country.
BioCx, the European maker of generic painkillers, is down 8 percent.
BioMorphine, a German company, is a leading provider of generic oxycodone to the U,S., U.A.E. and Europe.
Its stock has risen 30 percent over the past year.
Boeing, which has been investing heavily in medical technology, is an early leader in the market.
The company recently reported record sales of more then $30 billion, including a record $4.2 billion in the first quarter of 2017.
The aerospace giant, which also makes the 747 and 747-200, also reported record revenue in the quarter, which included $1.6 billion in profits.
The jet maker also reported strong quarterly sales and profits.
The U.S. pharmaceutical company Boehringer Ingelheim, which is headquartered in Munich, said it expects to report earnings in the second quarter of 2019.
The pharmaceutical company said its sales increased 6 percent in the most recent quarter.
CVS Health is another major provider of prescription pain medication.
The drug company’s share price rose 12 percent to $25.57, while the shares of MedImmune Inc., which provides vaccines for chronic pain, rose 7 percent to around $38.
The share of Medi-Sys Pharmaceuticals Inc., the maker of opioid medicines, fell 3 percent to about $36.50.
Vivendi HealthCare Inc., an independent insurer in the United States, is facing a lawsuit in California from the American Civil Liberties Union over the treatment of some patients with hepatitis C. The lawsuit accuses the insurer of misleading patients about the risk of hepatitis C, and of failing to provide proper diagnosis and treatment.
Aldi Nordstrom said on Thursday it is looking to raise $4 billion from investors.
Walmart is also preparing to increase its dividend by 5 percent in 2019 to $2.50 a share, a move that could make it the largest publicly traded retailer in the history of the United Kingdom.
This is an edited version of Fortune’s latest list of the most undervalued stocks in the stock market.